-
Innovation Ranking
NewInnovation Ranking – Celldex Therapeutics Inc
Celldex Therapeutics Inc (Celldex) is a bio-pharmaceutical company that discovers, develops, and commercializes targeted immunotherapy and other biologics for the treatment of various types of cancers. The company’s developmental pipeline comprises therapeutic antibodies, antibody drug conjugates (ADCs), protein-based therapeutics, immune system modulators and vaccine for unmet medical needs. Its key products in development include CDX-1140; CDX-527, CDX-0159. Celldex’s products find application in the treatment of various indications such as brain cancer, triple negative breast cancer, lymphoma/leukemia, melanoma, and renal cell...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Varlilumab in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Varlilumab in Mantle Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Varlilumab in Mantle Cell Lymphoma Drug Details: Varlilumab (CDX-1127) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Varlilumab in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Varlilumab in Marginal Zone B-cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Varlilumab in Marginal Zone B-cell Lymphoma Drug Details: Varlilumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CDX-1140 in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CDX-1140 in Epithelial Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CDX-1140 in Epithelial Ovarian Cancer Drug Details: CDX-1140 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Varlilumab in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Varlilumab in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Varlilumab in Glioblastoma Multiforme (GBM) Drug Details: Varlilumab (CDX-1127) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Varlilumab in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Varlilumab in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Varlilumab in Diffuse Large B-Cell Lymphoma Drug Details: Varlilumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Varlilumab in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Varlilumab in Follicular Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Varlilumab in Follicular Lymphoma Drug Details: Varlilumab (CDX-1127) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CDX-1140 in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CDX-1140 in Endometrial Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CDX-1140 in Endometrial Cancer Drug Details: CDX-1140 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CDX-1140 in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CDX-1140 in Fallopian Tube Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CDX-1140 in Fallopian Tube Cancer Drug Details: CDX-1140 is under...